Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Noninvasive phosphorus magnetic resonance spectroscopic imaging predicts outcome to first-line chemotherapy in newly diagnosed patients with diffuse large B-cell lymphoma.

Arias-Mendoza F, Payne GS, Zakian K, Stubbs M, O'Connor OA, Mojahed H, Smith MR, Schwarz AJ, Shukla-Dave A, Howe F, Poptani H, Lee SC, Pettengel R, Schuster SJ, Cunningham D, Heerschap A, Glickson JD, Griffiths JR, Koutcher JA, Leach MO, Brown TR.

Acad Radiol. 2013 Sep;20(9):1122-9. doi: 10.1016/j.acra.2013.04.013.

2.

In vivo monitoring response to chemotherapy of human diffuse large B-cell lymphoma xenografts in SCID mice by 1H and 31P MRS.

Huang MQ, Nelson DS, Pickup S, Qiao H, Delikatny EJ, Poptani H, Glickson JD.

Acad Radiol. 2007 Dec;14(12):1531-9.

3.

18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation.

Cashen AF, Dehdashti F, Luo J, Homb A, Siegel BA, Bartlett NL.

J Nucl Med. 2011 Mar;52(3):386-92. doi: 10.2967/jnumed.110.082586.

5.

Peripheral blood lymphocyte/monocyte ratio predicts outcome for patients with diffuse large B cell lymphoma after standard first-line regimens.

Li YL, Pan YY, Jiao Y, Ning J, Fan YG, Zhai ZM.

Ann Hematol. 2014 Apr;93(4):617-26. doi: 10.1007/s00277-013-1916-9.

PMID:
24141331
6.

Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.

Phan J, Mazloom A, Medeiros LJ, Zreik TG, Wogan C, Shihadeh F, Rodriguez MA, Fayad L, Fowler N, Reed V, Horace P, Dabaja BS.

J Clin Oncol. 2010 Sep 20;28(27):4170-6. doi: 10.1200/JCO.2009.27.3441.

PMID:
20713859
7.

Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.

Nowakowski GS, LaPlant B, Macon WR, Reeder CB, Foran JM, Nelson GD, Thompson CA, Rivera CE, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Gascoyne RD, Habermann TM, Witzig TE.

J Clin Oncol. 2015 Jan 20;33(3):251-7. doi: 10.1200/JCO.2014.55.5714.

PMID:
25135992
8.

Survival of patients with transformed lymphoma in the rituximab era.

Guirguis HR, Cheung MC, Piliotis E, Spaner D, Berinstein NL, Imrie K, Zhang L, Buckstein R.

Ann Hematol. 2014 Jun;93(6):1007-14. doi: 10.1007/s00277-013-1991-y.

PMID:
24414374
9.

Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients.

Park YH, Lee JJ, Ryu MH, Kim SY, Kim DH, Do YR, Lee KH, Oh SJ, Kim YK, Suh CW, Heo DS, Ryoo BY, Kim JK, Song HS, Lee WS, Kim HJ, Bang YJ, Yang SH, Sohn SK, Kang YK; Lymphoma Study Division of the Korean Cancer Study Group..

Ann Hematol. 2006 Apr;85(4):257-62.

PMID:
16416337
10.

Impact of consolidation radiation therapy in stage III-IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging.

Dorth JA, Prosnitz LR, Broadwater G, Diehl LF, Beaven AW, Coleman RE, Kelsey CR.

Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):762-7. doi: 10.1016/j.ijrobp.2011.12.067.

PMID:
22420972
11.

Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study.

Tzankov A, Leu N, Muenst S, Juskevicius D, Klingbiel D, Mamot C, Dirnhofer S.

J Hematol Oncol. 2015 Jun 14;8:70. doi: 10.1186/s13045-015-0168-7.

12.

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.

Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, MacPherson N, O'Reilly S, Spinelli JJ, Sutherland J, Wilson KS, Gascoyne RD, Connors JM.

J Clin Oncol. 2005 Aug 1;23(22):5027-33.

PMID:
15955905
13.

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.

Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, Pocock C, Ardeshna KM, Radford JA, McMillan A, Davies J, Turner D, Kruger A, Johnson P, Gambell J, Linch D.

Lancet. 2013 May 25;381(9880):1817-26. doi: 10.1016/S0140-6736(13)60313-X.

14.

Prognostic Value of Anemia and C-Reactive Protein Levels in Diffuse Large B-Cell Lymphoma.

Adams HJ, de Klerk JM, Fijnheer R, Heggelman BG, Dubois SV, Nievelstein RA, Kwee TC.

Clin Lymphoma Myeloma Leuk. 2015 Nov;15(11):671-9. doi: 10.1016/j.clml.2015.07.639.

PMID:
26361646
15.

Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma.

Weiss L, Melchardt T, Habringer S, Boekstegers A, Hufnagl C, Neureiter D, Hopfinger G, Greil R, Egle A.

Ann Oncol. 2014 Jan;25(1):171-6. doi: 10.1093/annonc/mdt481.

PMID:
24299961
16.

Evaluation of early imaging response after chemoembolization of hepatocellular carcinoma by phosphorus-31 magnetic resonance spectroscopy-initial experience.

Yuan Z, Ye XD, Dong S, Xu LC, Xiao XS.

J Vasc Interv Radiol. 2011 Aug;22(8):1166-73. doi: 10.1016/j.jvir.2011.04.010.

PMID:
21703872
17.

NMR metabolic and physiological markers of therapeutic response.

Lee SC, Poptani H, Delikatny EJ, Pickup S, Nelson DS, Schuster SJ, Nasta SD, Svoboda J, Goldstein SC, Wallace SG, Loevner LA, Mellon EA, Reddy R, Glickson JD.

Adv Exp Med Biol. 2011;701:129-35. doi: 10.1007/978-1-4419-7756-4_18.

PMID:
21445779
18.

High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy.

Li ZM, Huang JJ, Xia Y, Zhu YJ, Zhao W, Wei WX, Jiang WQ, Lin TY, Huang HQ, Guan ZZ.

Eur J Haematol. 2012 Jun;88(6):510-7. doi: 10.1111/j.1600-0609.2012.01778.x.

PMID:
22413767
19.

B cell non-Hodgkin's lymphoma: experience from a tertiary care cancer center.

Prakash G, Sharma A, Raina V, Kumar L, Sharma MC, Mohanti BK.

Ann Hematol. 2012 Oct;91(10):1603-11. doi: 10.1007/s00277-012-1491-5.

PMID:
22584851
20.

Supplemental Content

Support Center